A detailed history of Fifth Third Bancorp transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 74 shares of COLL stock, worth $2,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74
Previous 70 5.71%
Holding current value
$2,476
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$31.4 - $39.07 $125 - $156
4 Added 5.71%
74 $2,000
Q2 2024

Jul 22, 2024

BUY
$31.36 - $39.99 $533 - $679
17 Added 32.08%
70 $2,000
Q1 2024

Apr 23, 2024

BUY
$31.23 - $40.91 $156 - $204
5 Added 10.42%
53 $2,000
Q2 2023

Jul 25, 2023

SELL
$21.06 - $24.0 $12,678 - $14,448
-602 Reduced 92.62%
48 $1,000
Q1 2023

Apr 24, 2023

BUY
$23.0 - $29.88 $13,846 - $17,987
602 Added 1254.17%
650 $15,000
Q2 2022

Aug 04, 2022

BUY
$14.22 - $20.88 $682 - $1,002
48 New
48 $1,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.14B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.